Biotech Values

[mskatiescarletohara]

DNDN....what a stunner! How often do you find an advisory panel endorsing data from two failed pivotals? The question about efficacy was rephrased? Sounds like compassion was in play today, congratulations to the DNDN longs.

Still remains to be seen if the FDA will approve on May 15 or issue a approvable letter pending review of additional data. Nonetheless, it's still a positive for the DNDN longs, and those afflicted with prostate cancer. Either it goes to market in a month or it's delayed, either way it appears it's headed to market.

katie...